| | | 5-HIAA | HVA | MHPG |
---|
HTR3A Genotype | Sex | n | Mean ± SD (nmol/L) | Fa pa
| Fb pb
| Mean ± SD (nmol/L) | Fa pa
| Fb pb
| Mean ± SD (nmol/L) | Fa pa
| Fb pb
|
---|
T/Tc
| All | 3 | 105 ± 52 | F = 5.75 | F = 10.22 | 203 ± 124 | F = 3.25 | F = 7.95 | 44 ± 5 | F = 0.45 | F = 0.29 |
C/Tc
| | 27 | 117 ± 36 | p = 0.02 | p = 0.002 | 211 ± 67 | p = 0.07 | p = 0.006 | 43 ± 8 | p = 0.50 | p = 0.75 |
C/C | | 60 | 90 ± 35 | | | 166 ± 71 | | | 42 ± 7 | | |
T/Tc
| Men | 1 | 52 | F = 0.31 | F = 0.96 | 113 | F = 0.75 | F = 1.49 | 49 | F = 0.20 | F = 0.49 |
C/Tc
| | 11 | 106 ± 33 | p = 0.58 | p = 0.33 | 193 ± 50 | p = 0.39 | p = 0.23 | 44 ± 9 | p = 0.66 | p = 0.49 |
C/C | | 40 | 90 ± 37 | | | 159 ± 11 | | | 43 ± 7 | | |
T/Tc
| Women | 2 | 131 ± 34 | F = 8.55 | F = 9.75 | 248 ± 137 | F = 2.49 | F = 4.05 | 41 ± 3 | F = 0.68 | F = 1.00 |
C/Tc
| | 16 | 124 ± 37 | p = 0.006 | p = 0.004d
| 224 ± 76 | p = 0.12 | p = 0.05e
| 42 ± 7 | p = 0.42 | p = 0.32f
|
C/C | | 20 | 92 ± 30 | | | 179 ± 64 | | | 40 ± 6 | | |
- 5-HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylglycol. Statistical comparisons done on monoamine metabolite residuals correcteda and uncorrectedb for back length. c T/T and C/T genotypes were combined in the analyses. d Correction for use of oral contraceptives, F = 5.56, p = 0.02. e Correction for use of oral contraceptives, F = 1.76, p = 0.19. f Correction for use of oral contraceptives, F = 0.17, p = 0.68. Analysing heterosis, i.e. comparing homo- vs heterozygotes: All subjects 5-HIAA: F = 10.03, p = 0.002 (F = 5.71, p = 0.02 after correction for back length). All subjects HVA: F = 7.13, p = 0.009 (F = 2.28, p = 0.10). Men 5-HIAA: F = 1.96, p = 0.17 (F = 1.00, p = 0.32). Men HVA: 2.33, p = 0.13 (F = 1.40, p = 0.24). Women 5-HIAA: F = 6.73, p = 0.01 (F = 5.65, p = 0.02 and F = 3.76, p = 0.06 corrected for back length and use of oral contraceptives, respectively). Women HVA: F = 2.49, p = 0.12 (F = 1.03, p = 0.32 and F = 0.98, p = 0.33 corrected for back length and use of oral contraceptives, respectively).